Research programme: vaccines - CyTuVax

Next Previous
Drug Profile

Research programme: vaccines - CyTuVax

Alternative Names: PanCaVax

Latest Information Update: 20 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyTuVax
  • Class Vaccines
  • Mechanism of Action Immunogenetic stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Malignant melanoma; Pancreatic cancer

Most Recent Events

  • 20 Nov 2015 Preclinical trials in Malignant melanoma in Netherlands (unspecified route)
  • 20 Nov 2015 Preclinical trials in Pancreatic cancer in Netherlands (unspecified route)
  • 20 Nov 2015 Preclinical trials in Cytomegalovirus infections (Prevention) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top